

Key Statistics (USD)

| | |
|----------------------------|----------|
| Price | 67.05 |
| Market Cap | 84.09 B |
| Enterprise Value | 108.98 B |
| PEG | - |
| 52 weeks high | 78.94 |
| 52 weeks low | 56.56 |
| Beta (5Y-monthly) | 0.39 |
| Dividend yield % | 4.26 |
| EPS (TTM) | 0.21 |
| DPS | 2.75 |
| One year stock performance | -11.69% |

| Growth Rates | Company | Sector |
|----------------------------------|---------|---------|
| Revenue (Q/Q last year) | 15.77% | 21.31% |
| Net earnings (YTD/YTD last year) | -97.72% | 6.32% |
| Net earnings (Q/Q last year) | 11.48% | -43.79% |

| Margins | Company | Sector |
|----------------------------------|---------|---------|
| Gross Profit margin | 81.48% | 64.88% |
| EBITDA margin | - | - |
| EBT margin | 6.76% | -23.44% |
| Net Profit margin | 0.36% | -18.96% |
| Gross Profit margin (5Y average) | 81.92% | 63.10% |
| EBT margin (5Y average) | 35.98% | -8.98% |

| Key Ratios | Company | Sector |
|---------------|---------|--------|
| Current Ratio | 1.37 | 3.54 |
| Quick Ratio | 1.26 | 2.73 |
| Cash Ratio | - | - |
| ROE | 1.47 | -17.56 |
| ROA | 0.43 | -7.98 |
| ROC | 0.50 | -10.66 |
| D/E | 1.47 | 0.39 |

| Valuation Metrics | Company | Sector (median) |
|-------------------|---------|-----------------|
| P/E (NTM) | 9.79 | -6.05 |
| P/E (TTM) | 688.47 | 19.49 |
| P/B (TTM) | 4.64 | 6.12 |
| P/Sales (TTM) | 3.42 | 9.96 |

Firm's Brief Description.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu.

Sector Overview

- The global biotechnology market size is expected to reach USD 2.44 trillion by 2028 and to expand at a CAGR of 15.83% from 2021 to 2028.
- The global oncology drugs market was valued at \$128,351 million in 2019, and is projected to reach \$222,380 million by 2027, registering a CAGR of 7.4%.
- The bioinformatics application segment is expected to expand at the fastest CAGR of 21.2% from 2021 to 2028 owing to the increasing alliances to coordinate and advance the adoption of informatics tools.

Fundamental Analysis

Gilead Sciences Inc. stock performance during the past year fall by 11.69%, mainly because key patents recently expired. Taking into consideration the last 12 months, the company outperformed its competitors on net earnings while underperformed on revenue growth. Moreover, gross profit 81.48% and net profit margin 0.36% are higher than the sector average which are 64.88% and -18.96% respectively. We can observe the same also for the 5 year averages. Furthermore, the company is very effective in reinvesting its profits as it generates positive returns compared to sector's average negative returns. More specifically, with a Return on Equity (ROE) ratio of 1.47 outperforms the sector's average which stands at -17.56, a Return on Assets (ROA) of 0.43 while the sector's is at -7.98 and a Return on Capital (ROC) of 0.50 while the sector's ratio is at -10.66. On the other side, Debt to Equity is higher than the sector's average and it can be seen as a red flag, but most of the debt is long term and therefore not a big issue for Gilead. Finally, GILD has a high dividend yield of 4.26%, a low Price to Book value, a low Price to Sales value and a P/E ratio for the next 12 months higher than the sector's median and below 10, indicating it as an undervalued stock.

Target Price (1 year forward): 74.80 \$

DISCLAIMER

THE FINANCE CLUB OF UNIVERSITY OF MACEDONIA, THESSALONIKI, GREECE

The Finance Club of University of Macedonia - www.financeclub.gr is an independent non-profitable student organization founded by students of the University of Macedonia, Greece (UoM - www.uom.gr) that aims to build strong relations between the market and the University. Though based in the University of Macedonia, it also operates via associates in Aristotle University of Thessaloniki, Greece and other institutions. The Club's goal is to give its members the chance to view the market in a more practical approach rather than solely relying on the abstract knowledge offered by the university. In order to achieve this goal, the Club organizes various events like conferences, workshops and seminars. Moreover, its members are able to cooperate with companies by taking up real case projects to work on along with the managers of the associated companies. In addition, the Club is trying to build and expand its network among students, market professionals and professors therefore giving its members a very broad pool of potential partners and employers.

This report has been compiled by the authors mentioned above and published by them via the Finance Club UoM site and many other platforms. The club confirms that the authors are active members at the time this article is published but emphasizes the fact that opinions and views given by the authors in this article are their own views. Finance Club UoM takes no responsibility for the completeness or correctness of information provided. No investment advice is given with the text above and the reader should not take any financial position based on the information published in this article. The Club recommends extensive research by the reader before investing in any financial asset. General this report may be based on the information extracted from various sources including but not limited to various companies' and statistical agencies' websites, online portals, third-party research, annual reports etc. No representation or warranty of any kind is or may be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, any projections or futuristic statement contained herein or any underlying assumptions. This article may include descriptions, statements, estimates and projections/futuristic statements with respect to current and anticipated performance of the underlying. Such statements, estimates and projections reflect various assumptions and best estimates made by the participants concerning anticipated results, whose assumptions and estimates may or may not prove to be accurate or correct. There are no assurances whatsoever that any statements, estimates or projections contained in this article, including without limitation any financial or business projections, accurately present in all material respects the underlying's financial and/or business position as of the respective dates specified and the results of its operations for any respective periods indicated. No copyright or trademark infringement is intended in any form.

© Copyright 2020. Finance Club UoM